Jennison Associates LLC Phathom Pharmaceuticals, Inc. Transaction History
Jennison Associates LLC
- $162 Billion
- Q4 2024
A detailed history of Jennison Associates LLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 7,062,507 shares of PHAT stock, worth $42.3 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
7,062,507
Previous 5,866,389
20.39%
Holding current value
$42.3 Million
Previous $106 Million
45.93%
% of portfolio
0.04%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding PHAT
# of Institutions
142Shares Held
74.8MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$60.6 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$44.7 Million13.31% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$24.5 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$20.9 Million9.52% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$17.5 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $235M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...